3.92
Schlusskurs vom Vortag:
$3.97
Offen:
$3.99
24-Stunden-Volumen:
277.54K
Relative Volume:
0.67
Marktkapitalisierung:
$206.82M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-197.68M
KGV:
-1.0426
EPS:
-3.76
Netto-Cashflow:
$-158.88M
1W Leistung:
+9.80%
1M Leistung:
-20.33%
6M Leistung:
-46.67%
1J Leistung:
+24.44%
Kodiak Sciences Inc Stock (KOD) Company Profile
Firmenname
Kodiak Sciences Inc
Sektor
Branche
Telefon
650-281-0850
Adresse
1200 PAGE MILL RD, PALO ALTO, CA
Vergleichen Sie KOD mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
KOD
Kodiak Sciences Inc
|
3.92 | 184.67M | 0 | -197.68M | -158.88M | -3.76 |
![]()
ONC
Beone Medicines Ltd Adr
|
257.00 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
443.82 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.282 | 41.83M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
85.54 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
483.07 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-12-09 | Hochstufung | Jefferies | Hold → Buy |
2024-09-05 | Eingeleitet | H.C. Wainwright | Neutral |
2023-12-11 | Fortgesetzt | Goldman | Sell |
2023-11-17 | Hochstufung | CapitalOne | Equal Weight → Overweight |
2023-07-27 | Herabstufung | UBS | Buy → Neutral |
2023-07-25 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
2023-07-25 | Herabstufung | JP Morgan | Neutral → Underweight |
2023-07-24 | Herabstufung | CapitalOne | Overweight → Equal Weight |
2023-07-24 | Herabstufung | Jefferies | Buy → Hold |
2022-11-15 | Eingeleitet | CapitalOne | Overweight |
2022-08-02 | Herabstufung | Citigroup | Neutral → Sell |
2022-02-24 | Herabstufung | JP Morgan | Overweight → Neutral |
2022-02-11 | Eingeleitet | Goldman | Buy |
2022-02-02 | Hochstufung | JP Morgan | Neutral → Overweight |
2021-05-11 | Hochstufung | ROTH Capital | Neutral → Buy |
2021-03-12 | Eingeleitet | Evercore ISI | Outperform |
2021-03-01 | Herabstufung | Barclays | Equal Weight → Underweight |
2021-02-17 | Herabstufung | ROTH Capital | Buy → Neutral |
2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2020-12-17 | Eingeleitet | Berenberg | Buy |
2020-12-16 | Eingeleitet | UBS | Buy |
2020-12-11 | Eingeleitet | Citigroup | Neutral |
2020-11-30 | Herabstufung | JP Morgan | Overweight → Neutral |
2020-11-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2020-11-13 | Herabstufung | Goldman | Buy → Neutral |
2020-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
2020-03-03 | Eingeleitet | Goldman | Buy |
2020-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
2020-02-06 | Eingeleitet | SunTrust | Buy |
2020-01-08 | Eingeleitet | ROTH Capital | Buy |
2020-01-03 | Eingeleitet | Jefferies | Buy |
2019-12-24 | Eingeleitet | JP Morgan | Overweight |
2019-10-15 | Bestätigt | Chardan Capital Markets | Buy |
2019-02-20 | Eingeleitet | Chardan Capital Markets | Buy |
2018-10-29 | Eingeleitet | Barclays | Overweight |
2018-10-29 | Eingeleitet | BofA/Merrill | Buy |
2018-10-29 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Kodiak Sciences Inc Aktie (KOD) Neueste Nachrichten
Kodiak Sciences Holds 2025 Annual Stockholders Meeting - TipRanks
Kodiak Sciences to Present at 2025 Jefferies Global Healthcare C - GuruFocus
Kodiak Sciences Reveals Latest Retinal Disease Breakthroughs at Major Healthcare Conference - Stock Titan
Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference - Yahoo Finance
Kodiak Sciences’ SWOT analysis: eye disease biotech stock at crossroads - Investing.com Australia
Kodiak Sciences’ SWOT analysis: eye disease biotech stock at crossroads By Investing.com - Investing.com India
Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus - The Globe and Mail
Kodal Minerals Nears Export Permit For Mali Lithium Project - Finimize
Kodiak Sciences Inc Reports Q1 2025 Earnings: EPS of -$1.09 Misses Estimates, No Revenue Reported - GuruFocus
KOD Plans to Unveil Key Developments as Phase 3 Trials Progress - GuruFocus
KOD Plans to Unveil Key Developments as Phase 3 Trials Progress | KOD Stock News - GuruFocus
Kodiak Sciences Announces Recent Business Highlights and First Q - GuruFocus
Kodiak Sciences Reports Deeper Q1 Loss: What 3 Key Phase 3 Trials Mean for Future Growth - Stock Titan
Kodiak Sciences (KOD) Projected to Post Earnings on Wednesday - Defense World
Kodiak Sciences Inc. (NASDAQ:KOD) Shares Acquired by Dimensional Fund Advisors LP - Defense World
MetLife Investment Management LLC Makes New $209,000 Investment in Kodiak Sciences Inc. (NASDAQ:KOD) - The AM Reporter
MetLife Investment Management LLC Invests $209,000 in Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Wells Fargo & Company MN Sells 2,710 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Ratio Review: Analyzing Kodiak Sciences Inc (KOD)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Retinal vein occlusion Market: Epidemiology, Therapies, - openPR.com
BlackRock, Inc. Reduces Stake in Kodiak Sciences Inc. - GuruFocus
Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatilit - GuruFocus
CND Life Sciences Closes $13.5M Series A Equity Round to Continue Growth and Innovation in Neurodiagnostics - The Malaysian Reserve
Breakthrough Eye Disease Platform: Kodiak Sciences Reveals 7 Major Advances at ARVO 2025 - Stock Titan
Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases - Yahoo Finance
Wet Age-Related Macular Degeneration Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Therapies, NICE Approvals, Prevalence, and Companies by DelveInsight - Barchart.com
JPMorgan Chase & Co. Increases Holdings in Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Kodiak Sciences Inc [KOD] Shares Rise 9.62 % on Wednesday - knoxdaily.com
A year in review: Kodiak Sciences Inc (KOD)’s performance in the last year - uspostnews.com
Insider’s View: Deciphering Kodiak Sciences Inc (KOD)’s Financial Health Through Ratios - DWinneX
April 2025's Promising Penny Stocks - Yahoo
Stealth biotech bags rights to VelaVigo bispecific in $440M deal - Fierce Biotech
AMKR Shares Experience Decline in Value - knoxdaily.com
Age Related Vision Dysfunction Market to Reach New Heights - openPR.com
Age Related Vision Dysfunction Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Kodiak Sciences Inc., Outlook Therapeutics, Eye point Pharmaceuticals - The Globe and Mail
Why Coffee Prices Remain Volatile - The Globe and Mail
Prudential Financial Inc. Sells 65,400 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Wet Age-Related Macular Degeneration Therapeutics Market Size - openPR.com
Sei Investments Co. Sells 69,599 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Kodiak Sciences stock hits 52-week low at $2.15 - Investing.com India
HC Wainwright Comments on Kodiak Sciences Q2 Earnings - Defense World
HC Wainwright Forecasts Kodiak Sciences Q1 Earnings - Defense World
Down -28.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Kodiak Sciences (KOD) - Yahoo Finance
H.C. Wainwright holds Kodiak Sciences stock at Neutral, $3 target By Investing.com - Investing.com South Africa
H.C. Wainwright holds Kodiak Sciences stock at Neutral, $3 target - Investing.com
Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus - MSN
Charles Schwab Investment Management Inc. Sells 6,758 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Finanzdaten der Kodiak Sciences Inc-Aktie (KOD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Kodiak Sciences Inc-Aktie (KOD) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
BORGESON JOHN A. | See Remarks |
Jun 12 '24 |
Sale |
2.92 |
1,558 |
4,549 |
179,544 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):